These analyses validated our previous epigenomic observations and revealed the significant enrichment of AP‐1 members (FOSL1–FOSL2) and RUNX factors (RUNX1–RUNX2), both of which were more evident in the context of the MS phenotype (Fig. 4D). This evidence concerns the gene RUNX2 and myeloid sarcoma.